



# Press Release

February 9, 2011

Rundbuckstrasse 6  
CH – 8212 Neuhausen am Rheinfall / Switzerland  
[www.lifewatch.com](http://www.lifewatch.com)

## **LifeWatch AG to report on Fourth Quarter 2010 and Full Fiscal Year 2010 Results on March 1, 2011**

**Press release and Letter to Shareholders at 7:00 a.m. CET (01:00 EST)  
Analyst and media conference held in Zurich at 10:00 a.m. CET  
International Live Conference Call/Web cast at 10:00 a.m. CET**

*Neuhausen am Rheinfall/Switzerland* – LifeWatch AG (SIX Swiss Exchange: LIFE) will report on its results for the fourth quarter 2010 and full fiscal year 2010 on Tuesday, March 1, 2011 in Zurich.

A PDF-version of the invitation and a registration form can be found at the end of this message.

### **Press Release and Letter to Shareholders at 7:00 a.m. CET (01:00 a.m. EST)**

LifeWatch will publish internationally the results for the fourth quarter 2010 and full fiscal year 2010 in a press release and letter to shareholders at 7:00 a.m. CET.

### **Analyst and media conference at 10:00 a.m. CET**

LifeWatch will report on the fourth quarter 2010 and full fiscal year 2010 results at an English-speaking analyst and media conference will take place in Zurich on

**Tuesday, March 1, 2011; 10:00 a.m. CET,  
at the Zunfthaus zur Safran, Limmatquai 54, 8001 Zurich/Switzerland**

Please confirm your participation at the analyst and media conference by returning the registration form by February 24, 2011.

### **International Live Conference Call/Web cast at 10:00 a.m. CET**

For international participants, a combined conference call and audio web cast, accompanied by presentation visuals, is broadcast online at 10:00 a.m. CET (04.00 a.m. EST) live from the conference in Zurich. Further information regarding the audio web cast and respective technical requirements can be found in the Investor Relations section of the LifeWatch Website [www.irlifewatch.com](http://www.irlifewatch.com) in due time. An archived version of the web cast will remain available for viewing.

The local dial-in numbers for the conference call are as follows:

+ 41 (0)91 610 56 00 (Europe)

+ 44 (0)203 059 58 62 (UK)

+ 1 (1)866 291 41 66 (USA – Toll-free)

All participants are requested to dial in at least ten minutes prior to the call. No PIN is required to access the call.

**For further information please contact:**

Sensus Investor and Public Relations, Zürich:

Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email [lifewatch@sensus.ch](mailto:lifewatch@sensus.ch)

**About LifeWatch AG**

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit [www.lifewatch.com](http://www.lifewatch.com).

**Sign-up** for customized E-mail alerts and documentation requests is available at <http://production.investis.com/lifewatch/alert-service/>

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.